Current thinking on genital herpes

Current Opinion in Infectious Diseases

Volumn 27, Issue 1, 2014, Pages 75-83

  Hofstetter, Annika M ^a   Rosenthal, Susan L ^a   Stanberry, Lawrence R ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

genital; herpes simplex virus; infection

Indexed keywords

VACCINE;

ANTIVIRAL THERAPY; ASYMPTOMATIC INFECTION; GENITAL HERPES; HERPES SIMPLEX VIRUS; HOST; HUMAN; IMMUNITY; LATENT PERIOD; NONHUMAN; PRIMARY INFECTION; PROPHYLAXIS; RECURRENT DISEASE; REINFECTION; REVIEW; SCREENING; VIRUS REACTIVATION; VIRUS SHEDDING;

ANTIVIRAL AGENTS; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HOST-PATHOGEN INTERACTIONS; HUMANS; SIMPLEXVIRUS; VIRUS SHEDDING;

EID: 84891829765     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000029     Document Type: Review

References (133)

1. Stewart JA, Reef SE, Pellett PE, et al. Herpesvirus infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1995; 21 (Suppl 1): S114-S120.
2. Hull HF, Blumhagen JD, Benjamin D, et al. Herpes simplex viral pneumonitis in childhood. J Pediatr 1984; 104:211-215. (Pubitemid 14188926)
3. Herget GW, Riede UN, Schmitt-Graff A, et al. Generalized herpes simplex virus infection in an immunocompromised patient: report of a case and review of the literature. Pathol Res Pract 2005; 201:123-129. (Pubitemid 40443826)
4. Carney O, Ross E, Bunker C, et al. A prospective study of the psychological impact on patients with a first episode of genital herpes. Genitourin Med 1994; 70:40-45. (Pubitemid 24101412)
5. Longo D, Koehn K. Psychosocial factors and recurrent genital herpes: a review of prediction and psychiatric treatment studies. Int J Psychiatry Med 1993; 23:99-117. (Pubitemid 23212188)
6. Mindel A, Marks C. Psychological symptoms associated with genital herpes virus infections: epidemiology and approaches to management. CNS Drugs 2005; 19:303-312. (Pubitemid 40593601)
7. Thompson C, Whitley R. Neonatal herpes simplex virus infections: where are we now? Adv Exp Med Biol 2011; 697:221-230.
8. Barnabas RV, Celum C. Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions. Curr HIV Res 2012; 10:228-237.
9. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002; 185:45-52. (Pubitemid 34043015)
10. Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and metaanalysis of longitudinal studies. AIDS 2006; 20:73-83. (Pubitemid 41818117)
11. Schacker T, Zeh J, Hu H, et al. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002; 186:1718-1725. (Pubitemid 35463503)
12. Schacker T, Ryncarz AJ, Goddard J, et al. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998; 280:61-66. (Pubitemid 28414998)
13. McClelland RS, Wang CC, Overbaugh J, et al. Association between cervical shedding of herpes simplex virus and HIV-1. AIDS 2002; 16:2425-2430. (Pubitemid 35471690)
14. Nilsen A, Kasubi MJ, Mohn SC, et al. Herpes simplex virus infection and genital ulcer disease among patients with sexually transmitted infections in Dar es Salaam, Tanzania. Acta Derm Venereol 2007; 87:355-359.
15. Mertz KJ, Trees D, Levine WC, et al. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J Infect Dis 1998; 178:1795-1798. (Pubitemid 28558157)
16. Paz-Bailey G, Rahman M, Chen C, et al. Changes in the etiology of sexually transmitted diseases in Botswana between 1993 and 2002: implications for the clinical management of genital ulcer disease. Clin Infect Dis 2005; 41:1304-1312. (Pubitemid 41532674)
17. Mwansasu A, Mwakagile D, Haarr L, et al. Detection of HSV-2 in genital ulcers from STD patients in Dar es Salaam, Tanzania. J Clin Virol 2002; 24:183-192. (Pubitemid 34150171)
18. Lewis DA, Muller E, Steele L, et al. Prevalence and associations of genital ulcer and urethral pathogens in men presenting with genital ulcer syndrome to primary healthcare clinics in South Africa. Sex Transm Dis 2012; 39:880-885.
19. Beyrer C, Jitwatcharanan K, Natpratan C, et al. Molecular methods for the diagnosis of genital ulcer disease in a sexually transmitted disease clinic population in northern Thailand: predominance of herpes simplex virus infection. J Infect Dis 1998; 178:243-246. (Pubitemid 28328100)
20. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis 2002; 186 (Suppl 1): S3-S28. (Pubitemid 35178845)
21. Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ 2008; 86:805-812.
22. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296:964-973. (Pubitemid 44285373)
23. Centers for Disease Control and Prevention. Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years: United States, 2005-2008. MMWR Morb Mortal Wkly Rep 2010; 59:456-459.
24. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337:1105-1111. (Pubitemid 27444100)
25. Xu F, Lee FK, Morrow RA, et al. Seroprevalence of herpes simplex virus type 1 in children in the United States. J Pediatr 2007; 151:374-377. (Pubitemid 47432656)
26. Centers for Disease Control and Prevention. Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years-United States, 2005-2008. MMWR Morb Mortal Wkly Rep 2010; 59:456-459.
27. Haddow LJ, Dave B, Mindel A, et al. Increase in rates of herpes simplex virus type 1 as a cause of anogenital herpes in western Sydney, Australia, between 1979 and 2003. Sex Transm Infect 2006; 82:255-259. (Pubitemid 43901599)
28. Tran T, Druce JD, Catton MC, et al. Changing epidemiology of genital herpes simplex virus infection in Melbourne, Australia, between 1980 and 2003. Sex Transm Infect 2004; 80:277-279. (Pubitemid 39070788)
29. Kortekangas-Savolainen O, Vuorinen T. Trends in herpes simplex virus type 1 and 2 infections among patients diagnosed with genital herpes in a Finnish sexually transmitted disease clinic, 1994-2002. Sex Transm Dis 2007; 34:37-40. (Pubitemid 46041506)
30. Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis 2003; 30:797-800. (Pubitemid 37229492)
31. Ryder N, Jin F, McNulty AM, et al. Increasing role of herpes simplex virus type 1 in first-episode anogenital herpes in heterosexual women and younger men who have sex with men, 1992-2006. Sex Transm Infect 2009; 85:416-419.
32. Janier M, Scieux C, Meouchi R, et al. Virological, serological and epidemiological study of 255 consecutive cases of genital herpes in a sexually transmitted disease clinic of Paris (France): a prospective study. Int J STD AIDS 2006; 17:44-49. (Pubitemid 43110456)
33. Bernstein DI, Bellamy AR, Hook EW 3rd, et al. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis 2013; 56:344-351.
34. Wald A. Knowledge is power: a case for wider herpes simplex virus serologic testing. JAMA Pediatr 2013; 167:689-690.
35. Whitley RJ. Changing epidemiology of herpes simplex virus infections. Clin Infect Dis 2013; 56:352-353.
36. Cook ML, Stevens JG. Pathogenesis of herpetic neuritis and ganglionitis in mice: evidence for intra-axonal transport of infection. Infect Immun 1973; 7:272-288.
37. Baringer JR. Recovery of herpes simplex virus from human sacral ganglions. N Engl J Med 1974; 291:828-830.
38. Stanberry LR, Bourne N, Bravo FJ, et al. Capsaicin-sensitive peptidergic neurons are involved in the zosteriform spread of herpes simplex virus infection. J Med Virol 1992; 38:142-146.
39. Stanberry LR. Capsaicin interferes with the centrifugal spread of virus in primary and recurrent genital herpes simplex virus infections. J Infect Dis 1990; 162:29-34. (Pubitemid 20223945)
40. Tata S, Johnston C, Huang ML, et al. Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa. J Infect Dis 2010; 201:499-504.
41. Schiffer JT, Swan D, Al Sallaq R, et al. Rapid localized spread and immunologic containment define herpes simplex virus-2 reactivation in the human genital tract. Elife 2013; 2:e00288.
42. Mark KE, Wald A, Magaret AS, et al. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis 2008; 198:1141-1149.
43. Lafferty WE, Coombs RW, Benedetti J, et al. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med 1987; 316:1444-1449. (Pubitemid 17079092)
44. Davison AJ. Evolution of sexually transmitted and sexually transmissible human herpesviruses. Ann N Y Acad Sci 2012; 1230:E37-E49.
45. Gentry GA, Lowe M, Alford G, et al. Sequence analyses of herpesviral enzymes suggest an ancient origin for human sexual behavior. Proc Natl Acad Sci USA 1988; 85:2658-2661.
46. Krause PR, Stanberry LR, Bourne N, et al. Expression of the herpes simplex virus type 2 latency-associated transcript enhances spontaneous reactivation of genital herpes in latently infected guinea pigs. J Exp Med 1995; 181:297-306.
47. Yoshikawa T, Hill JM, Stanberry LR, et al. The characteristic site-specific reactivation phenotypes of HSV-1 and HSV-2 depend upon the latencyassociated transcript region. J Exp Med 1996; 184:659-664. (Pubitemid 26324119)
48. Bertke AS, Patel A, Krause PR. Herpes simplex virus latency-associated transcript sequence downstream of the promoter influences type-specific reactivation and viral neurotropism. J Virol 2007; 81:6605-6613. (Pubitemid 46878064)
49. Engelberg R, Carrell D, Krantz E, et al. Natural history of genital herpes simplex virus type 1 infection. Sex Transm Dis 2003; 30:174-177. (Pubitemid 36184367)
50. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994; 121:847-854.
51. Corey L, Adams HG, Brown ZA, et al. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 1983; 98:958-972. (Pubitemid 13053413)
52. Wald A, Huang ML, Carrell D, et al. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis 2003; 188:1345-1351. (Pubitemid 37433705)
53. Mertz GJ. Asymptomatic shedding of herpes simplex virus 1 and 2: implications for prevention of transmission. J Infect Dis 2008; 198:1098-1100.
54. Wald A, Zeh J, Selke S, et al. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995; 333:770-775.
55. Wald A, Corey L, Cone R, et al. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest 1997; 99:1092-1097. (Pubitemid 27123647)
56. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342:844-850. (Pubitemid 30165207)
57. Koelle DM, Benedetti J, Langenberg A, et al. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med 1992; 116:433-437.
58. Wald A, Zeh J, Selke S, et al. Genital shedding of herpes simplex virus among men. J Infect Dis 2002; 186 (Suppl 1):S34-S39. (Pubitemid 35178847)
59. Tronstein E, Johnston C, Huang ML, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA 2011; 305:1441-1449.
60. Schiffer JT, Wald A, Selke S, et al. The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions. J Infect Dis 2011; 204:554-561.
61. Crespi CM, Cumberland WG, Wald A, et al. Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling. Sex Transm Infect 2007; 83:359-364. (Pubitemid 47242482)
62. Phipps W, Saracino M, Magaret A, et al. Persistent genital herpes simplex virus-2 shedding years following the first clinical episode. J Infect Dis 2011; 203:180-187.
63. Mertz GJ, Benedetti J, Ashley R, et al. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992; 116:197-202.
64. Mertz GJ, Schmidt O, Jourden JL, et al. Frequency of acquisition of firstepisode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis 1985; 12:33-39. (Pubitemid 15143207)
65. Sucato G, Wald A, Wakabayashi E, et al. Evidence of latency and reactivation of both herpes simplex virus (HSV)-1 and HSV-2 in the genital region. J Infect Dis 1998; 177:1069-1072. (Pubitemid 28155164)
66. Roest RW, Carman WF, Maertzdorf J, et al. Genotypic analysis of sequential genital herpes simplex virus type 1 (HSV-1) isolates of patients with recurrent HSV-1 associated genital herpes. J Med Virol 2004; 73:601-604. (Pubitemid 38857212)
67. Roest RW, Maertzdorf J, Kant M, et al. High incidence of genotypic variance between sequential herpes simplex virus type 2 isolates from HIV-1-seropositive patients with recurrent genital herpes. J Infect Dis 2006; 194:1115-1118. (Pubitemid 44547651)
68. Buchman TG, Roizman B, Nahmias AJ. Demonstration of exogenous genital reinfection with herpes simplex virus type 2 by restriction endonuclease fingerprinting of viral DNA. J Infect Dis 1979; 140:295-304. (Pubitemid 10189470)
69. Gerson M, Portnoy J, Hamelin C. Consecutive infections with herpes simplex virus types 1 and 2 within a three-week period. J Infect Dis 1984; 149:655. (Pubitemid 14139062)
70. Kit S, Trkula D, Qavi H, et al. Sequential genital infections by herpes simplex viruses types 1 and 2: restriction nuclease analyses of viruses from recurrent infections. Sex Transm Dis 1983; 10:67-71. (Pubitemid 13036476)
71. Nahmias AJ, Josey WE, Naib ZM, et al. Antibodies to Herpesvirus hominis types 1 and 2 in humans. I. Patients with genital herpetic infections. Am J Epidemiol 1970; 91:539-546.
72. Langenberg AG, Corey L, Ashley RL, et al. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 1999; 341:1432-1438. (Pubitemid 29513459)
73. Xu F, Schillinger JA, Sternberg MR, et al. Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994. J Infect Dis 2002; 185:1019-1024. (Pubitemid 34297758)
74. Breinig MK, Kingsley LA, Armstrong JA, et al. Epidemiology of genital herpes in Pittsburgh: serologic, sexual, and racial correlates of apparent and inapparent herpes simplex infections. J Infect Dis 1990; 162:299-305. (Pubitemid 20239940)
75. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347:1652-1661. (Pubitemid 35340783)
76. Stanberry LR, Rosenthal SL, Mills L, et al. Longitudinal risk of herpes simplex virus (HSV) type 1, HSV type 2, and cytomegalovirus infections among young adolescent girls. Clin Infect Dis 2004; 39:1433-1438. (Pubitemid 39518204)
77. Bryson Y, Dillon M, Bernstein DI, et al. Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study. J Infect Dis 1993; 167:942-946. (Pubitemid 23088267)
78. Cherpes TL, Meyn LA, Krohn MA, et al. Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. Clin Infect Dis 2003; 37:319-325. (Pubitemid 36976487)
79. Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997; 337:509-515. (Pubitemid 27352016)
80. Chan T, Barra NG, Lee AJ, et al. Innate and adaptive immunity against herpes simplex virus type 2 in the genital mucosa. J Reprod Immunol 2011; 88:210-218.
81. Leoni V, Gianni T, Salvioli S, et al. Herpes simplex virus glycoproteins gH/gL and gB bind Toll-like receptor 2, and soluble gH/gL is sufficient to activate NF-kappaB. J Virol 2012; 86:6555-6562.
82. Cunningham AL, Diefenbach RJ, Miranda-Saksena M, et al. The cycle of human herpes simplex virus infection: virus transport and immune control. J Infect Dis 2006; 194 (Suppl 1):S11-S18. (Pubitemid 44420867)
83. Casrouge A, Zhang SY, Eidenschenk C, et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 2006; 314:308-312. (Pubitemid 44571977)
84. Sancho-Shimizu V, Perez de Diego R, Lorenzo L, et al. Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. J Clin Invest 2011; 121:4889-4902.
85. Herman M, Ciancanelli M, Ou YH, et al. Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood. J Exp Med 2012; 209:1567-1582.
86. Lafaille FG, Pessach IM, Zhang SY, et al. Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells. Nature 2012; 491:769-773.
87. Niehues T, Reichenbach J, Neubert J, et al. Nuclear factor kappaB essential modulator-deficient child with immunodeficiency yet without anhidrotic ectodermal dysplasia. J Allergy Clin Immunol 2004; 114:1456-1462. (Pubitemid 39575905)
88. Guo Y, Audry M, Ciancanelli M, et al. Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. J Exp Med 2011; 208:2083-2098.
89. Bochud PY, Magaret AS, Koelle DM, et al. Polymorphisms in TLR2 are associated with increased viral shedding and lesional rate in patients with genital herpes simplex virus Type 2 infection. J Infect Dis 2007; 196:505-509. (Pubitemid 47206095)
90. Milligan GN, Bernstein DI, Bourne N. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J Immunol 1998; 160:6093-6100. (Pubitemid 28298073)
91. Wakim LM, Jones CM, Gebhardt T, et al. CD8(\+) T-cell attenuation of cutaneous herpes simplex virus infection reduces the average viral copy number of the ensuing latent infection. Immunol Cell Biol 2008; 86:666-675.
92. Khanna KM, Lepisto AJ, Decman V, et al. Immune control of herpes simplex virus during latency. Curr Opin Immunol 2004; 16:463-469. (Pubitemid 38881674)
93. Roizman B, Zhou G, Du T. Checkpoints in productive and latent infections with herpes simplex virus 1: conceptualization of the issues. J Neurovirol 2011; 17:512-517.
94. Held K, Derfuss T. Control of HSV-1 latency in human trigeminal ganglia-current overview. J Neurovirol 2011; 17:518-527.
95. Margolis TP, Imai Y, Yang L, et al. Herpes simplex virus type 2 (HSV-2) establishes latent infection in a different population of ganglionic neurons than HSV-1: role of latency-associated transcripts. J Virol 2007; 81:1872-1878. (Pubitemid 46214459)
96. Johnson AJ, Chu CF, Milligan GN. Effector CD4\+T-cell involvement in clearance of infectious herpes simplex virus type 1 from sensory ganglia and spinal cords. J Virol 2008; 82:9678-9688.
97. Wakim LM, Waithman J, van Rooijen N, et al. Dendritic cell-induced memory T cell activation in nonlymphoid tissues. Science 2008; 319:198-202.
98. Koelle DM, Posavad CM, Barnum GR, et al. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 1998; 101:1500-1508. (Pubitemid 28166848)
99. Zhu J, Koelle DM, Cao J, et al. Virus-specific CD8\+T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007; 204:595-603. (Pubitemid 46457082)
100. Schiffer JT, Abu-Raddad L, Mark KE, et al. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc Natl Acad Sci USA 2010; 107:18973-18978.
101. Schiffer JT, Corey L. Rapid host immune response and viral dynamics in herpes simplex virus-2 infection. Nat Med 2013; 19:280-290.
102. Dudley KL, Bourne N, Milligan GN. Immune protection against HSV-2 in Bcell-deficient mice. Virology 2000; 270:454-463. (Pubitemid 30333692)
103. Morrison LA, Zhu L, Thebeau LG. Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells. J Virol 2001; 75:1195-1204. (Pubitemid 32094678)
104. Seppanen M, Meri S, Notkola IL, et al. Subtly impaired humoral immunity predisposes to frequently recurring genital herpes simplex virus type 2 infection and herpetic neuralgia. J Infect Dis 2006; 194:571-578. (Pubitemid 44297840)
105. Li Z, Palaniyandi S, Zeng R, et al. Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc Natl Acad Sci USA 2011; 108:4388-4393.
106. Blank H, Haines HG. Experimental human reinfection with herpes simplex virus. J Invest Dermatol 1973; 61:223-225.
107. Gallichan WS, Rosenthal KL. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J Infect Dis 1998; 177:1155-1161. (Pubitemid 28194251)
108. Mark HD. Asymptomatic sexually active adolescents and young adults should not be screened for herpes simplex virus. JAMA Pediatr 2013; 167:691-692.
109. Wald A, Ashley-Morrow R. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin Infect Dis 2002; 35 (Suppl 2):S173-S182. (Pubitemid 35178328)
110. U.S. Preventive Services Task Force. Screening for genital herpes. http://www.uspreventiveservicestaskforce.org/uspstf05/herpes/herpesrs.htm. [Accessed 19 August 2013]
111. Ross K, Johnston C, Wald A. Herpes simplex virus type 2 serological testing and psychosocial harm: a systematic review. Sex Transm Infect 2011; 87:594-600.
112. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59 (RR-12):1-110.
113. Gupta R, Wald A, Krantz E, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis 2004; 190:1374-1381. (Pubitemid 39332176)
114. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350:11-20. (Pubitemid 38032179)
115. Wald A, Selke S, Warren T, et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis 2006; 33:529-533. (Pubitemid 44318975)
116. Williams JR, Jordan JC, Davis EA, et al. Suppressive valacyclovir therapy: impact on the population spread of HSV-2 infection. Sex Transm Dis 2007; 34:123-131. (Pubitemid 46673212)
117. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
118. Cohen CR, Brown J, Moscicki AB, et al. A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel(R)) in healthy young women administered twice daily for 14 days. PLoS One 2011; 6:e16258.
119. Rupp R, Rosenthal SL, Stanberry LR. VivaGel (SPL7013 Gel): a candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int J Nanomed 2007; 2:561-566.
120. Cates WJr. After CAPRISA 004: time to re-evaluate the HIV lexicon. Lancet 2010; 376:495-496.
121. Effect of tenofovir on genital herpes simplex virus (HSV) shedding. http://clinicaltrials.gov/ct2/show?termtenofovir\+gel\+hsv3. [Accessed 12 September 2013]
122. Field HJ, Vere Hodge RA. Recent developments in antiherpesvirus drugs. Br Med Bull 2013; 106:213-249.
123. Tyring S, Wald A, Zadeikis N, et al. ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo-and valacyclovir-controlled, dose-finding study. J Infect Dis 2012; 205:1100-1110.
124. Reyes M, Shaik NS, Graber JM, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003; 163:76-80. (Pubitemid 36091604)
125. Stanberry L.Genital and perinatal herpes simplex virus infections. In: Stanberry L, Rosenthal SL, editors. Sexually transmitted diseases: vaccines, prevention, and control., 2nd ed. London: Academic Press; 2013. pp. 273-313.
126. Mo A, Musselli C, Chen H, et al. A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(\+) and CD8(\+) cellular immunity and protective efficacy. Vaccine 2011; 29:8530-8541.
127. Wald A, Koelle DM, Fife K, et al. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. Vaccine 2011; 29:8520-8529.
128. Biological efficacy study of HerpV vaccine with QS-21 to treat subjects with recurrent genital herpes. http://clinicaltrials.gov/ct2/show/NCT0 1687595? termAGENUS\+HERPES1. [Accessed 19 August 2013]
129. Safety and immunogenicity study of therapeutic HSV-2 vaccine. http://clinicaltrials.gov/ct2/show/NCT01667341?termgenocea\+therapeutic\+ hsv\+vaccine1. [Accessed 15 August 2013]
130. Belshe RB, Leone PA, Bernstein DI, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012; 366:34-43.
131. Dudek TE, Torres-Lopez E, Crumpacker C, et al. Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa. J Infect Dis 2011; 203:1434-1441.
132. Balachandran N, Oba DE, Hutt-Fletcher LM. Antigenic cross-reactions among herpes simplex virus types 1 and 2, Epstein-Barr virus, and cytomegalovirus. J Virol 1987; 61:1125-1135. (Pubitemid 17044026)
133. Shin H, Iwasaki A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 2012; 491:463-467.